Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer Microenvironment

Molecular and Cellular Proteomics

Volumn 17, Issue 2, 2018, Pages 270-289

  Worzfeld, Thomas ^a,b,c,d   Finkernagel, Florian ^b,c   Reinartz, Silke ^c   Konzer, Anne ^b   Adhikary, Till ^b,c   Nist, Andrea ^a,c   Stiewe, Thorsten ^a,c   Wagner, Uwe ^b,d   Looso, Mario ^b,c   Graumann, Johannes ^b   Müller, Rolf ^b,c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c Fachbereich Medizin der Universitat Marburg   (Germany)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; INTEGRIN; PROTEOME; TRANSCRIPTOME; TUMOR PROTEIN;

ARTICLE; ASCITES CELL; CANCER PATIENT; CANCER PROGNOSIS; CELL ADHESION; CELL COMMUNICATION; CELL ISOLATION; CLINICAL OUTCOME; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; OVARY CANCER; PRIORITY JOURNAL; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; OVARY TUMOR;

FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85041705525     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.RA117.000400     Document Type: Article

References (103)

1. Colombo, N., Peiretti, M., Parma, G., Lapresa, M., Mancari, R., Carinelli, S., Sessa, C., Castiglione, M., and Group, E. G. W. (2010) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21, v23–v30
2. Pogge von Strandmann, E. R., S; Wagner, U., and Müller, R. (2017) Tumor-host cell interactions in ovarian cancer: pathways to therapy failure. Trends Cancer 3, 137–148
3. Leinster, D. A., Kulbe, H., Everitt, G., Thompson, R., Perretti, M., Gavins, F. N., Cooper, D., Gould, D., Ennis, D. P., Lockley, M., McNeish, I. A., Nourshargh, S., and Balkwill, F. R. (2012) The peritoneal tumour microenvironment of high-grade serous ovarian cancer. J. Pathol. 227, 136–145
4. Negus, R. P., Stamp, G. W., Hadley, J., and Balkwill, F. R. (1997) Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150, 1723–1734
5. Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., and Muller, R. (2017) The unique molecular and cellular microenvironment of ovarian cancer. Front. Oncol. 7, 24
6. Iwanicki, M. P., Davidowitz, R. A., Ng, M. R., Besser, A., Muranen, T., Merritt, M., Danuser, G., Ince, T. A., and Brugge, J. S. (2011) Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 1, 144 –157
7. Lessan, K., Aguiar, D. J., Oegema, T., Siebenson, L., and Skubitz, A. P. (1999) CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am. J. Pathol. 154, 1525–1537
8. Finkernagel, F., Reinartz, S., Lieber, S., Adhikary, T., Wortmann, A., Hoff-mann, N., Bieringer, T., Nist, A., Stiewe, T., Jansen, J. M., Wagner, U., Muller-Brusselbach, S., and Muller, R. (2016) The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. Oncotarget 7, 75339–75352
9. Condeelis, J., and Pollard, J. W. (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263–266
10. Gabrilovich, D. I., Ostrand-Rosenberg, S., and Bronte, V. (2012) Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268
11. Qian, B. Z., and Pollard, J. W. (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39–51
12. Sica, A., and Bronte, V. (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117, 1155–1166
13. Burt, B. M., Rodig, S. J., Tilleman, T. R., Elbardissi, A. W., Bueno, R., and Sugarbaker, D. J. (2011) Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 117, 5234 –5244
14. Quatromoni, J. G., and Eruslanov, E. (2012) Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am. J. Transl. Res. 4, 376–389
15. Reinartz, S., Schumann, T., Finkernagel, F., Wortmann, A., Jansen, J. M., Meissner, W., Krause, M., Schworer, A. M., Wagner, U., Muller-Brusselbach, S., and Muller, R. (2014) Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int. J. Cancer 134, 32–42
16. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, M. L., Knutson, K. L., Chen, L., and Zou, W. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949
17. Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., Rubin, S. C., and Coukos, G. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213
18. Marth, C., Windbichler, G. H., Hausmaninger, H., Petru, E., Estermann, K., Pelzer, A., and Mueller-Holzner, E. (2006) Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int. J. Gynecol. Cancer 16, 1522–1528
19. Windbichler, G. H., Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Muller-Holzner, E., and Marth, C. (2000) Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br. J. Cancer 82, 1138–1144
20. Preston, C. C., Maurer, M. J., Oberg, A. L., Visscher, D. W., Kalli, K. R., Hartmann, L. C., Goode, E. L., and Knutson, K. L. (2013) The ratios of CD8 T cells to CD4CD25 FOXP3 and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS ONE 8, e80063
21. Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jung-bluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., Kepner, J., Odunsi, T., Ritter, G., Lele, S., Chen, Y. T., Ohtani, H., Old, L. J., and Odunsi, K. (2005) Intraepithelial CD8 tumor-infiltrating lymphocytes and a high CD8/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 102, 18538–18543
22. Hermans, C., Anz, D., Engel, J., Kirchner, T., Endres, S., and Mayr, D. (2014) Analysis of FoxP3 T-regulatory cells and CD8 T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers. PLoS ONE 9, e111757
23. Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., Old, L. J., and Odunsi, K. (2010) Tumor-infiltrating NY-ESO-1-specific CD8 T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 107, 7875–7880
24. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., and Gwyther, S. G. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205–216
25. Rustin, G. J., Timmers, P., Nelstrop, A., Shreeves, G., Bentzen, S. M., Baron, B., Piccart, M. J., Bertelsen, K., Stuart, G., Cassidy, J., and Eisenhauer, E. (2006) Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J. Clin. Oncol. 24, 45–51
26. Yates, A., Akanni, W., Amode, M. R., Barrell, D., Billis, K., Carvalho-Silva, D., Cummins, C., Clapham, P., Fitzgerald, S., Gil, L., Giron, C. G., Gordon, L., Hourlier, T., Hunt, S. E., Janacek, S. H., Johnson, N., Juettemann, T., Keenan, S., Lavidas, I., Martin, F. J., Maurel, T., McLaren, W., Murphy, D. N., Nag, R., Nuhn, M., Parker, A., Patricio, M., Pignatelli, M., Rahtz, M., Riat, H. S., Sheppard, D., Taylor, K., Thormann, A., Vullo, A., Wilder, S. P., Zadissa, A., Birney, E., Harrow, J., Muffato, M., Perry, E., Ruffier, M., Spudich, G., Trevanion, S. J., Cunningham, F., Aken, B. L., Zerbino, D. R., and Flicek, P. (2016) Ensembl 2016. Nucleic Acids Res. 44, D710 –D716
27. Mi, H., Dong, Q., Muruganujan, A., Gaudet, P., Lewis, S., and Thomas, P. D. (2010) PANTHER version 7: improved phylogenetic trees, or-thologs and collaboration with the Gene Ontology Consortium. Nucleic Acids Res. 38, D204–D210
28. Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., Diehn, M., West, R. B., Plevritis, S. K., and Alizadeh, A. A. (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945
29. Ramilowski, J. A., Goldberg, T., Harshbarger, J., Kloppmann, E., Lizio, M., Satagopam, V. P., Itoh, M., Kawaji, H., Carninci, P., Rost, B., and Forrest, A. R. (2015) A draft network of ligand-receptor-mediated mul-ticellular signalling in human. Nat. Communications 6, 7866
30. Reinartz, S., Finkernagel, F., Adhikary, T., Rohnalter, V., Schumann, T., Schober, Y., Nockher, W. A., Nist, A., Stiewe, T., Jansen, J. M., Wagner, U., Muller-Brusselbach, S., and Muller, R. (2016) A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol. 17, 108
31. Baker, P. R., and Chalkley, R. J. (2014) MS-viewer: a web-based spectral viewer for proteomics results. Mol. Cell. Proteomics 13, 1392–1396
32. Shevchenko, A., Wilm, M., Vorm, O., and Mann, M. (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850–858
33. Rappsilber, J., Ishihama, Y., and Mann, M. (2003) Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectro-spray, and LC/MS sample pretreatment in proteomics. Anal. Chem. 75, 663–670
34. Peng, J., Elias, J. E., Thoreen, C. C., Licklider, L. J., and Gygi, S. P. (2003) Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J. Proteome Res. 2, 43–50
35. Elias, J. E., and Gygi, S. P. (2007) Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4, 207–214
36. Zhang, H., Liu, T., Zhang, Z., Payne, S. H., Zhang, B., McDermott, J. E., Zhou, J. Y., Petyuk, V. A., Chen, L., Ray, D., Sun, S., Yang, F., Chen, L., Wang, J., Shah, P., Cha, S. W., Aiyetan, P., Woo, S., Tian, Y., Gritsenko, M. A., Clauss, T. R., Choi, C., Monroe, M. E., Thomas, S., Nie, S., Wu, C., Moore, R. J., Yu, K. H., Tabb, D. L., Fenyo, D., Bafna, V., Wang, Y., Rodriguez, H., Boja, E. S., Hiltke, T., Rivers, R. C., Sokoll, L., Zhu, H., Shih Ie, M., Cope, L., Pandey, A., Zhang, B., Snyder, M. P., Levine, D. A., Smith, R. D., Chan, D. W., Rodland, K. D., and Investigators, C. (2016) Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166, 755–765
37. Chevallet, M., Diemer, H., Van Dorssealer, A., Villiers, C., and Rabilloud, T. (2007) Toward a better analysis of secreted proteins: the example of the myeloid cells secretome. Proteomics 7, 1757–1770
38. Rabilloud, T. (2009) Membrane proteins and proteomics: love is possible, but so difficult. Electrophoresis 30, S174–S180
39. Santoni, V., Molloy, M., and Rabilloud, T. (2000) Membrane proteins and proteomics: un amour impossible? Electrophoresis 21, 1054–1070
40. Tan, S., Tan, H. T., and Chung, M. C. (2008) Membrane proteins and membrane proteomics. Proteomics 8, 3924–3932
41. Wang, D. H., Guo, L., and Wu, X. H. (2015) Checkpoint inhibitors in immunotherapy of ovarian cancer. Tumour Biol. 36, 33–39
42. Colvin, E. K. (2014) Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front. Oncol. 4, 137
43. Burleson, K. M., Casey, R. C., Skubitz, K. M., Pambuccian, S. E., Oegema, T. R., Jr, and Skubitz, A. P. (2004) Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol. Oncol. 93, 170 –181
44. Burleson, K. M., Hansen, L. K., and Skubitz, A. P. (2004) Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin. Exp. Metastasis 21, 685–697
45. Busuttil, R. A., George, J., Tothill, R. W., Ioculano, K., Kowalczyk, A., Mitchell, C., Lade, S., Tan, P., Haviv, I., and Boussioutas, A. (2014) A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response. Clin. Cancer Res. 20, 2761–2772
46. Cheon, D. J., Tong, Y., Sim, M. S., Dering, J., Berel, D., Cui, X., Lester, J., Beach, J. A., Tighiouart, M., Walts, A. E., Karlan, B. Y., and Orsulic, S. (2014) A collagen-remodeling gene signature regulated by TGF-beta signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin. Cancer Res. 20, 711–723
47. Cancer Genome Atlas Research, N. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474, 609 – 615
48. Riester, M., Wei, W., Waldron, L., Culhane, A. C., Trippa, L., Oliva, E., Kim, S. H., Michor, F., Huttenhower, C., Parmigiani, G., and Birrer, M. J. (2014) Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J. Natl. Cancer Inst. 106
49. Tang, Z., Ow, G. S., Thiery, J. P., Ivshina, A. V., and Kuznetsov, V. A. (2014) Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int. J. Cancer 134, 306–318
50. Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., Traficante, N., Fereday, S., Hung, J. A., Chiew, Y. E., Haviv, I., Australian Ovarian Cancer Study, G., Gertig, D., DeFazio, A., and Bowtell, D. D. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198 –5208
51. Goicoechea, S. M., Arneman, D., and Otey, C. A. (2008) The role of palladin in actin organization and cell motility. Eur. J. Cell Biol. 87, 517–525
52. Najm, P., and El-Sibai, M. (2014) Palladin regulation of the actin structures needed for cancer invasion. Cell Adh. Migr. 8, 29–35
53. Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., Nebuloni, M., van Rooijen, N., Mortarini, R., Beltrame, L., Marchini, S., Fuso Nerini, I., Sanfilippo, R., Casali, P. G., Pilotti, S., Galmarini, C. M., Anichini, A., Mantovani, A., D’Incalci, M., and Allavena, P. (2013) Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23, 249–262
54. Huang, S., Van Arsdall, M., Tedjarati, S., McCarty, M., Wu, W., Langley, R., and Fidler, I. J. (2002) Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst. 94, 1134 –1142
55. Reusser, N. M., Dalton, H. J., Pradeep, S., Gonzalez-Villasana, V., Jennings, N. B., Vasquez, H. G., Wen, Y., Rupaimoole, R., Nagaraja, A. S., Gharpure, K., Miyake, T., Huang, J., Hu, W., Lopez-Berestein, G., and Sood, A. K. (2014) Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biol. Ther. 15, 1061–1067
56. Robinson-Smith, T. M., Isaacsohn, I., Mercer, C. A., Zhou, M., Van Rooijen, N., Husseinzadeh, N., McFarland-Mancini, M. M., and Drew, A. F. (2007) Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 67, 5708–5716
57. Burkholder, B., Huang, R. Y., Burgess, R., Luo, S., Jones, V. S., Zhang, W., Lv, Z. Q., Gao, C. Y., Wang, B. L., Zhang, Y. M., and Huang, R. P. (2014) Tumor-induced perturbations of cytokines and immune cell networks. Biochim. Biophys. Acta 1845, 182–201
58. Sokol, C. L., and Luster, A. D. (2015) The chemokine system in innate immunity. Cold Spring Harbor Perspectives Biol. 7, 1–19
59. Kalinski, P. (2012) Regulation of immune responses by prostaglandin E2. J. Immunol. 188, 21–28
60. Houben, A. J., and Moolenaar, W. H. (2011) Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev. 30, 557–565
61. Ray, R., and Rai, V. (2017) Lysophosphatidic acid converts monocytes into macrophages in both mice and humans. Blood 129, 1177–1183
62. Knowlden, S. A., Capece, T., Popovic, M., Chapman, T. J., Rezaee, F., Kim, M., and Georas, S. N. (2014) Regulation of T cell motility in vitro and in vivo by LPA and LPA2. PLoS ONE 9, e101655
63. Oda, S. K., Strauch, P., Fujiwara, Y., Al-Shami, A., Oravecz, T., Tigyi, G., Pelanda, R., and Torres, R. M. (2013) Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunol. Res. 1, 245–255
64. Groh, V., Wu, J., Yee, C., and Spies, T. (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734 –738
65. Reiners, K. S., Topolar, D., Henke, A., Simhadri, V. R., Kessler, J., Sauer, M., Bessler, M., Hansen, H. P., Tawadros, S., Herling, M., Kronke, M., Hallek, M., and Pogge von Strandmann, E. (2013) Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell antitumor activity. Blood 121, 3658 –3665
66. Barquilla, A., and Pasquale, E. B. (2015) Eph receptors and ephrins: therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 55, 465–487
67. Worzfeld, T., and Offermanns, S. (2014) Semaphorins and plexins as therapeutic targets. Nat. Rev. Drug Discov. 13, 603–621
68. Blockus, H., and Chedotal, A. (2016) Slit-Robo signaling. Development 143, 3037–3044
69. Gara, R. K., Kumari, S., Ganju, A., Yallapu, M. M., Jaggi, M., and Chauhan, S. C. (2015) Slit/Robo pathway: a promising therapeutic target for cancer. Drug Discov. Today 20, 156 –164
70. Prasad, A., Qamri, Z., Wu, J., and Ganju, R. K. (2007) Slit-2/Robo-1 modulates the CXCL12/CXCR4-induced chemotaxis of T cells. J. Leu-koc. Biol. 82, 465–476
71. Wu, J. Y., Feng, L., Park, H. T., Havlioglu, N., Wen, L., Tang, H., Bacon, K. B., Jiang, Z., Zhang, X., and Rao, Y. (2001) The neuronal repellent Slit inhibits leukocyte chemotaxis induced by chemotactic factors. Nature 410, 948–952
72. Zhou, W. J., Geng, Z. H., Chi, S., Zhang, W., Niu, X. F., Lan, S. J., Ma, L., Yang, X., Wang, L. J., Ding, Y. Q., and Geng, J. G. (2011) Slit-Robo signaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis. Cell Res. 21, 609–626
73. Rama, N., Dubrac, A., Mathivet, T., Ni Charthaigh, R. A., Genet, G., Cristofaro, B., Pibouin-Fragner, L., Ma, L., Eichmann, A., and Chedotal, A. (2015) Slit2 signaling through Robo1 and Robo2 is required for retinal neovascularization. Nat. Med. 21, 483–491
74. Man, J., Shoemake, J., Zhou, W., Fang, X., Wu, Q., Rizzo, A., Prayson, R., Bao, S., Rich, J. N., and Yu, J. S. (2014) Sema3C promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation. Cell Rep. 9, 1812–1826
75. Esselens, C., Malapeira, J., Colome, N., Casal, C., Rodriguez-Manzaneque, J. C., Canals, F., and Arribas, J. (2010) The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. J. Biol. Chem. 285, 2463–2473
76. Malik, M. F., Satherley, L. K., Davies, E. L., Ye, L., and Jiang, W. G. (2016) Expression of semaphorin 3C in breast cancer and its impact on adhesion and invasion of breast cancer cells. Anticancer Res. 36, 1281–1286
77. Black, S. A., Nelson, A. C., Gurule, N. J., Futscher, B. W., and Lyons, T. R. (2016) Semaphorin 7a exerts pleiotropic effects to promote breast tumor progression. Oncogene 35, 5170–5178
78. Garcia-Areas, R., Libreros, S., Amat, S., Keating, P., Carrio, R., Robinson, P., Blieden, C., and Iragavarapu-Charyulu, V. (2014) Semaphorin7A promotes tumor growth and exerts a pro-angiogenic effect in macrophages of mammary tumor-bearing mice. Front. Physiol. 5, 17
79. Corrales, L., Ajona, D., Rafail, S., Lasarte, J. J., Riezu-Boj, J. I., Lambris, J. D., Rouzaut, A., Pajares, M. J., Montuenga, L. M., and Pio, R. (2012) Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J. Immunol. 189, 4674–4683
80. Holers, V. M. (2014) Complement and its receptors: new insights into human disease. Annu. Rev. Immunol. 32, 433–459
81. Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., Coukos, G., and Lambris, J. D. (2008) Modulation of the antitumor immune response by complement. Nat. Immunol. 9, 1225–1235
82. Nunez-Cruz, S., Gimotty, P. A., Guerra, M. W., Connolly, D. C., Wu, Y. Q., DeAngelis, R. A., Lambris, J. D., Coukos, G., and Scholler, N. (2012) Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neopla-sia 14, 994–1004
83. Pio, R., Corrales, L., and Lambris, J. D. (2014) The role of complement in tumor growth. Adv. Exp. Med. Biol. 772, 229–262
84. Rutkowski, M. J., Sughrue, M. E., Kane, A. J., Mills, S. A., and Parsa, A. T. (2010) Cancer and the complement cascade. Mol. Cancer Res. 8, 1453–1465
85. Schraufstatter, I. U., Discipio, R. G., Zhao, M., and Khaldoyanidi, S. K. (2009) C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J. Immunol. 182, 3827–3836
86. Bjorge, L., Hakulinen, J., Vintermyr, O. K., Jarva, H., Jensen, T. S., Iversen, O. E., and Meri, S. (2005) Ascitic complement system in ovarian cancer. Br. J. Cancer 92, 895–905
87. Wang, Q., Tang, Y., Yu, H., Yin, Q., Li, M., Shi, L., Zhang, W., Li, D., and Li, L. (2016) CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol. Carcinog. 55, 1688–1699
88. Schutyser, E., Struyf, S., Proost, P., Opdenakker, G., Laureys, G., Verhasselt, B., Peperstraete, L., Van de Putte, I., Saccani, A., Allavena, P., Mantovani, A., and Van Damme, J. (2002) Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J. Biol. Chem. 277, 24584–24593
89. Meng, F., Li, W., Li, C., Gao, Z., Guo, K., and Song, S. (2015) CCL18 promotes epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma. Int. J. Oncol. 46, 1109–1120
90. Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Chen, J., Liu, B., Deng, H., Wang, F., Lin, L., Yao, H., Su, F., Anderson, K. S., Liu, Q., Ewen, M. E., Yao, X., and Song, E. (2011) CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19, 541–555
91. Lin, L., Chen, Y. S., Yao, Y. D., Chen, J. Q., Chen, J. N., Huang, S. Y., Zeng, Y. J., Yao, H. R., Zeng, S. H., Fu, Y. S., and Song, E. W. (2015) CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer. Oncotarget 6, 34758–34773
92. Kulkarni-Datar, K., Orsulic, S., Foster, R., and Rueda, B. R. (2013) Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo. Cancer Lett. 339, 237–246
93. Curley, M. D., Therrien, V. A., Cummings, C. L., Sergent, P. A., Koulouris, C. R., Friel, A. M., Roberts, D. J., Seiden, M. V., Scadden, D. T., Rueda, B. R., and Foster, R. (2009) CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27, 2875–2883
94. Silva, I. A., Bai, S., McLean, K., Yang, K., Griffith, K., Thomas, D., Gines-tier, C., Johnston, C., Kueck, A., Reynolds, R. K., Wicha, M. S., and Buckanovich, R. J. (2011) Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71, 3991– 4001
95. Long, H., Xiang, T., Qi, W., Huang, J., Chen, J., He, L., Liang, Z., Guo, B., Li, Y., Xie, R., and Zhu, B. (2015) CD133 ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition. Oncotarget 6, 5846 –5859
96. Steg, A. D., Bevis, K. S., Katre, A. A., Ziebarth, A., Dobbin, Z. C., Alvarez, R. D., Zhang, K., Conner, M., and Landen, C. N. (2012) Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res. 18, 869–881
97. Zhang, J., Guo, X., Chang, D. Y., Rosen, D. G., Mercado-Uribe, I., and Liu, J. (2012) CD133 expression associated with poor prognosis in ovarian cancer. Mod. Pathol. 25, 456–464
98. Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., Matsumura, N., Abiko, K., Baba, T., Yamaguchi, K., Ueda, A., Hosoe, Y., Morita, S., Yokode, M., Shimizu, A., Honjo, T., and Konishi, I. (2015) Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015– 4022
99. Adhikary, T., Wortmann, A., Finkernagel, F., Lieber, S., Nist, A., Stiewe, T., Wagner, U., Muller-Brusselbach, S., Reinartz, S., and Muller, R. (2017) Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genomics 18, 243
100. Gillgrass, A. E., Chew, M. V., Krneta, T., and Ashkar, A. A. (2015) Over-expression of IL-15 promotes tumor destruction via NK1.1 cells in a spontaneous breast cancer model. BMC Cancer 15, 293
101. Steel, J. C., Waldmann, T. A., and Morris, J. C. (2012) Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33, 35–41
102. Yu, P., and Fu, Y. X. (2008) Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev. 19, 285–294
103. Hellwig, C. T., and Rehm, M. (2012) TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol. Cancer Ther. 11, 3–13